title: A mouse model of implant-associated infection.
abstract: Infections of implanted devices are of increasing frequency and importance, representing a significant limitation of many therapeutic modalities. There are puzzling features of implant-associated infection including the changes in microbial flora, the tendency to chronicity and impaired responses to conservative modes of treatment. The concept of the bacterial biofilm as a shielding mechanism generated by bacteria adherent to artificial surfaces has recently been proposed as an explanation for these features. The biofilm is a term applied to a complex comprising the implant surface, adherent bacteria and a specialized matrix enclosing the bacteria. The matrix of the biofilm is an electrostatically charged glue-like extracellular polymer derived by bacterial enzymes acting on tissue carbohydrates, formed by bacteria when adherent to surfaces. This matrix binds the bacteria to the surface providing a sequestration affording selective protection against harmful elements of the environment, especially mechanisms of host defenses and antimicrobial agents. These biological systems are complex to study because of the dynamic interaction of the microbial variables, host defenses, properties of synthetic materials and the biofilm matrix itself. There is a need for a laboratory model in which the variables can be controlled permitting the researcher to examine the outcomes of modifying one variable at a time in a planned and orderly manner. The practical way to attain this end is the conduct of studies in a stable reproducible animal model of localized biofilm-implant infection. Staphylococcus epidermidis is a representative of the class of microorganisms predominant in implant-associated infection. This paper describes the development of a model utilizing an implant-S. epidermidis-biofilm infection localized to the peritoneal cavity of the mouse. The natural history of the infection has been well documented and is stable in all respects for periods exceeding 3 months. This chronicity is especially advantageous in analyzing the impact of long-term therapeutic modalities and necessary periods of recovery and assessment. A representative example of an experimental use of this model to determine the relative efficacy of antibiotic therapeutic regimes is described, demonstrating its scope and efficacy.
authors.affiliation: Department of Medicine, Montreal General Hospital, PQ, Canada.
authors.forename: R F
authors.initials: RF
authors.lastname: Gagnon
authors.forename: G K
authors.initials: GK
authors.lastname: Richards
mesh_terms: D000818:Animals; D002404:Catheterization; D002408:Catheters, Indwelling / Q000009:adverse effects; D004195:Disease Models, Animal; D004357:Drug Synergism; D004359:Drug Therapy, Combination / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D051379:Mice; D008810:Mice, Inbred C57BL; D010529:Peritoneal Cavity; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects; D016459:Prosthesis-Related Infections / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology; D012293:Rifampin / Q000494:pharmacology / Q000627:therapeutic use; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000382:microbiology; D013212:Staphylococcus epidermidis / Q000187:drug effects / Q000254:growth & development / Q000276:immunology; D014640:Vancomycin / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D014640:Vancomycin; D012293:Rifampin